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Melissa Little is a Senior Principal Research Fellow at the Murdoch
Childrens Research Institute in Melbourne, Australia. Her lab has
studied kidney development and regeneration for over 20 years,
recently making notable advances in the generation of kidney
organoids from human iPSCs. We chatted with Melissa about her
career, her thoughts on the potential of the organoid and stem cell
fields, and what she hopes to achieve during her guest editorship with
Development.
How did you first become interested in biology?
As a child I was fascinated by the world around me. I spent a lot of
time camping in the Australian outback and found the plants,
animals and insects just fascinating.
You started your research career as a cancer biologist. How
did you eventuallymove on to studying kidney development?
At university I enrolled in science, assuming I was going to study
botany or zoology. But I loved my first-year course in physiology,
so my primary degree is actually in this area. Molecular biology was
just beginning during my PhD, so I worked on the molecular basis
of childhood cancer. I worked on Wilms’ tumour (a childhood
kidney cancer), before theWT1 gene was isolated, and later worked
onWT1 during my postdoc with Nicholas Hastie in Edinburgh. The
paradigm at that time was the two-hit hypothesis, i.e. that to get a
cancer you needed a hit in both copies of a tumour suppressor gene.
This hypothesis was based on retinoblastoma. Whereas the RB1
gene is expressed everywhere,WT1, by contrast, is very confined in
its expression during development, being restricted to the urogenital
system. So, while mutations in this gene give rise to kidney cancer,
they can also give rise to urogenital developmental anomalies.
When I returned to Australia I continued to work onWT1. However,
I was now based in a research institute with strong developmental
biology, such as the work of Peter Koopman and Toshiya Yamada,
so I changed direction to study WT1 and other genes in kidney
development.
How important were the years that you spent as a postdoc in
Edinburgh?
They had an enormous impact. I was a Royal Society Fellow, a
relatively new scheme at that time. I had offers in the USA, but I had
visited Nicholas in Edinburgh and really wanted to go to the MRC.
The unfortunate rule of that fellowship was that after two years I had
to return to Australia. But those years in the MRC were incredibly
important to me. They shaped how I work as a scientist, how I
interact with other scientists and how I approach answering
questions in science. Nicholas was an extremely positive mentor
and it was great to interact with people such as Wendy Bickmore,
Ian Jackson and Veronica Van Heyningen. It was a very formative
period of my career.
What are the challenges of establishing your lab in a
relatively isolated country like Australia?
One of the surprising things about being in the UKwas that amazing
scientists wandered through the building on a regular basis. That
didn’t happen in Australia. At that time there was no internet. The
latest copy of Nature arrived by sea. By the time it appeared in the
library it was already three months out of date. The isolation was
immense. It was very difficult to keep pace with what was
happening in science and to be at the forefront of anything because
we were so far behind in our capacity to know what else was
happening. I found that acutely oppressive when I came back to
Australia in 1992.
The internet completely changed that. It made international
collaboration feasible. We have real-time access to journals, we can
search for articles (and there is far more published now than anyone
could ever consume), we can electronically communicate in real
time, and so on. Science has become much more feasible at an
international level. Indeed, I have collaborations all around the
globe. However, Australia is still a very long way to anywhere. To
actually meet someone and talk face to face, which is quite
important, you must travel. And I travel extensively. I don’t think
people in the USA, for example, understand how taxing that is. I
remember doing a talk in Italy where I was on the ground for less
time than I was in the air. That is not that unusual, but it is pretty
physically brutal. So, Australians travel a lot because they have to.
You initially established your lab in Brisbane but recently
moved toMelbourne.Whatwere the reasons for this change?
I was at the University of Queensland for 23 years, and that is a very
long time to be in one place. I was in a really excellent institute, but
my research evolved to have a regeneration and stem cell aspect to it,
and I was relatively alone there in that respect. We were on a large
academic campus but quite remote from any hospital. I did my PhD
at the Queensland Medical Research Institute, which was located at
a hospital, and my thesis supervisor was the head of oncology and
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haematology, so I had been in an environment quite closely
associated with patients. I wanted to move back to an environment
that had, first of all, more stem cell biology, and second, access to
nephrologists. At the Murdoch Childrens Research Institute I am
physically located in a children’s hospital. I now have very close
associations with clinical geneticists and nephrologists, and we are
setting up a clinic where we derive patient stem cell lines. That has
been a really good part of the move.
What scientific questions is your lab working on at the
moment?
We are the kidney development, disease, repair and regeneration lab,
because we cover quite a wide range of kidney medicine. However,
everything we do is underpinned by our understanding of kidney
development. That is paramount. Mymost important message is that
stem cell biology on any organ requires you to understand that organ
intimately, so understanding development is key. We then use that
information to direct stem cells towards a kidney fate in order to
understand the relationship between development and disease. We
also look at what the postnatal kidney can or can’t do to repair itself.
We increasingly do human pluripotent stem cell work, but we still
investigate really fundamental developmental biology questions –
for example, how cells move, how they communicate with each
other, how they self-organise during development, and what genes
they express at what time.
Last year your lab published a high-profile paper in Nature,
reporting the generation of kidney organoids from human
iPSCs. Had this always been a goal of your lab?
It was a very specific and deliberate objective. Around 15 years ago,
when stem cell biology was really starting out (around the time that
Jamie Thomson derived the first human pluripotent stem cell lines
and Perry Bartlett showed evidence that there were postnatal stem
cells in the brain) I decided to change our research focus towards
regenerative medicine. We started with every option on the table.
We didn’t know what the postnatal kidney could do (we now know
that it can repair quite well but can’t regenerate), whether there were
postnatal stem cells or whether pluripotent stem cells could be
differentiated to a kidney fate. In fact, cellular reprogramming was
not even discussed at that time. There were a lot of things wewanted
to try for kidney regenerative medicine and the differentiation of
pluripotent stem cells was one of those. We were very systematic
and it took quite a long time to get there.
Your ‘mini-kidneys’ paper was extensively covered in the
mainstream media. How was your experience interacting
with the media?
It would be lovely to control the media but no one can. Sometimes I
cringe when I read what journalists write. They make broad
generalisations that might lead a patient to think that a cure is around
the corner, which is not true. This is the nature of the media. Some of
the interviews I did were, I think, poorly represented, whereas some of
them were great. You just roll with it. I don’t worry too much about
those events that are less than perfect, because I can’t control them.
The organoid field is a new and exciting area. How much
potential do you see in these techniques? Do you think it will
be possible to build a full organ in a dish, as the media
claims?
I think the media overestimates how far we have come. Organoids are
fascinating and a really exciting area, but we are a very long way away
from the clinic. ‘Organs in a dish’ is a funny expression, but I actually
believe that although we have a long way to go, we will genuinely get
there. I think there are some very short-term outcomes from this type of
research that fall into the remit of both fundamental and translational
biology. This is the first time that we can really start to pull apart human
development. The developing human itself is not something we have
had any access to, sowe do have a circular problem: how can you know
that what you are growing from a human cell is actually like a human?
Fromwhat we can see so far, however, it is a pretty remarkable model.
Hence, it really is a door into human development and that is very
exciting. From a more practical point of view, I am very interested in
what can be achieved with disease modelling and drug screening, even
personalised drug screening. However, we need to be vigilant about
howwe develop these tools. I am already seeing publications claiming
that organoids in a dish are accurately modelling disease but there are
such challenges with interclonal and experimental variation that I think
this still has to be definitively proven.
In the long term what we have is an approach where cells organise
themselves based on embryological principles, and this is amazing
from a fundamental science point of view. It will actually give us a
handle on how cells self-organise. We make a lot of assumptions
about how self-organisation works: cells differentially stick to each
other or make growth factors that make other cells wander towards
them. Now we have models where we can really pull that apart.
From a translational point of view, this sort of information will then
become an engineering challenge. How dowe build these structures
with a vasculature? How do we ensure a degree of anatomical
correctness that will be helpful for patients? For example, the kidney
organoids are currently of no value to a patient that requires a
transplant as they have no exiting ureter to remove the urine. The
kidney is, I would argue, the hardest thing you could ever try to
generate in vitro. It is architecturally completely constrained and its
function is totally dependent upon its anatomy. What we have at the
moment is too small and indeed dysplastic, so there is a lot that we
have to do better. But I think it is achievable with time.
I am really keen to encourage more of the
development field to embrace what stem
cells can give us
YourecentlystartedyourguesteditorshipwithDevelopment.
What do you hope to achieve in this year with us?
I am really keen to encourage more of the development field to
embrace what stem cells can give us, despite some reticence so far.
There are enormous opportunities here to look at development in a
different way. I want to open the door on investigating human
development using directed differentiation, especially using these
types of organogenic models (Little, 2016).
Howdo you see the relationship between the developmental
biology and stem cell fields evolving?
I think the nexus between developmental biology, cell biology and
stem cell biology is very exciting. There have been amazing advances
in imaging in the developmental biology field, particularly by those
working on what we would call ‘simple’ organisms, such as the worm
or the fly. They have phenomenal expertise in temporal-spatial
imaging, right down to the cellular level.Meanwhile, the cell biologists
are building tools to look at mechano-biology and real-time reporting
of pathway activity. To layer these advances on organoid creation from
a pluripotent cell in a dish, which is where stem cell biology is going, is
an enormously powerful approach.
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What kind of papers would you like to see more of in
Development?
I would like to see more papers looking at the fundamental processes
governing how cells organise themselves, whether that’s during
normal organogenesis in vivo or in a model in vitro. In the
past, molecular biology superseded fundamental, anatomical
developmental biology. Looking at aspects such as self-organisation
was put to one side because it was considered too descriptive. I think it
would be valuable to bring these fields back together and ask ‘what is
the molecular basis of self-organisation during embryogenesis?’.
We only have ourselves to blame if the
public loses interest in funding science
Youwereamemberof theAustralianGovernment’sStrategic
Reviewof Health andMedical Research in 2013. Do you think
it is important for scientists to play a role in policy?
Yes. I have had the opportunity to play a role in national scientific
policy throughout my career. I was not only involved in this review
but also in a seminal review of health and medical research in
Australia in 1998, when I was still a young scientist. I have played
roles within the Research Committee of the National Health
Medical Research Council, have advised the federal government on
science policy and around the debate on embryonic stem cells, and
the state government on biotechnology policy. I simply see this as
part of my professional obligations as a scientist. Too many young
scientists forget that science is a less tangible product, not like
making bricks or building boats.We are still primarily funded by tax
payers, in Australia almost exclusively. The tax payers expect health
outcomes, particularly in health and medical research. If we do not
engage, not just in policy discussions but also in public
communication, we only have ourselves to blame if the public
loses interest in funding science, or worse, loses faith in scientists.
One thing that I learnt very early is that there is a tendency for
scientists to think that we just need to educate everyone and then
they’ll understand why science is important. It is not about
education. People can make decisions without facts and often do.
They don’t need to be educated, they need to be engaged with.
That is a very different process. It means you need to be in the room,
to be having the conversation and discussing what you are doing
and why.
What is your advice for young scientists?
Follow your heart. You have to be fundamentally passionate about
finding an answer to a question. Have lateral vision and take every
opportunity that comes your way. Don’t assume that what you read
is right and question everything.
What would people be surprised to find out about you?
First and foremost, I’m a mum with two kids. In high school I was
the top student in my year at art and English, not science. Perhaps
this is why developmental biology is attractive to me. It is so
beautiful. I actually won a prize in creative writing as a teenager.
Someone recently asked me whether I still do any creative writing.
I write grants and manuscripts. That is a creative process, even if it is
describing data. I still paint for leisure, although not often enough.
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